{
    "medicine_id": "98fb83eccbfb6b7750048266dba38d4a9334ec03",
    "platform_id": "DB00710",
    "metadata": {
        "name": "Bondenza 150 mg Tablet film coated",
        "composition": "150 mg Ibandronate",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment and prevention of osteoporosis in postmenopausal women L13805 L13808",
            "contraindications": {
                "disease": "Patients experiencing an overdose may present with hypocalcemia hypophosphatemia upset stomach dyspepsia esophagitis and uclers L13805 L13808 Oral overdose can be managed by giving patients milk or antacids to bind excess unabsorbed ibandronate L13805 Overdoses can be managed by providing intravenous electrolytes and dialysis is not expected to remove excess drug from serum L13805 L13808",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Ibandronate is a nitrogen containing bisphosphonate used to treat and prevent osteoporosis in postmenopausal women L13805 L13808 The therapeutic index is wide as overdoses are not especially toxic and the duration of action is long as the half life can be up to 157 hours L13805 L13808 Patients should be counselled regarding the risk of upper GI adverse reactions hypocalcemia musculoskeletal pain osteonecrosis of the jaw atypical fractures of the femur and severe renal impairment L13805 L13808",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB01609",
                        "description": "The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Ibandronate is combined with Deferasirox"
                    },
                    {
                        "drugbank-id": "DB00112",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Bevacizumab is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00480",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Lenalidomide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01041",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Thalidomide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01268",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Sunitinib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01270",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Ranibizumab is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB02640",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Fumagillin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB02709",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Resveratrol is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04866",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB05288",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave acetate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06423",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Endostatin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06436",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06461",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Squalamine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06589",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Pazopanib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06647",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Volociximab is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08633",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when TNP 470 is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08910",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Pomalidomide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11366",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Roquinimex is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11727",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Endostar is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12056",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Trebananib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12081",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Anecortave is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12671",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Beloranib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB14864",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Brolucizumab is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00213",
                        "description": "The therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole"
                    },
                    {
                        "drugbank-id": "DB00338",
                        "description": "The therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole"
                    },
                    {
                        "drugbank-id": "DB00448",
                        "description": "The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole"
                    },
                    {
                        "drugbank-id": "DB00736",
                        "description": "The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole"
                    },
                    {
                        "drugbank-id": "DB01129",
                        "description": "The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole"
                    },
                    {
                        "drugbank-id": "DB05351",
                        "description": "The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole"
                    },
                    {
                        "drugbank-id": "DB13762",
                        "description": "The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexrabeprazole"
                    },
                    {
                        "drugbank-id": "DB11964",
                        "description": "The therapeutic efficacy of Ibandronate can be decreased when used in combination with Ilaprazole"
                    },
                    {
                        "drugbank-id": "DB00159",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Icosapent is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00244",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00328",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00461",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00465",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00469",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00482",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00500",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00533",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00554",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00573",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00580",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00586",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00605",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00712",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00749",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00784",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00788",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00795",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00812",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00814",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00821",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Carprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00861",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00936",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00939",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00945",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00991",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01009",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01014",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01050",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01250",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01283",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Lumiracoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01397",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01399",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01401",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01419",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Antrafenine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01424",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01435",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01600",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01628",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB02224",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Taxifolin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB03585",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04725",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Licofelone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04743",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04812",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04817",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Metamizole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04828",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB05095",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Cimicoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06725",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06736",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06737",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB07402",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08439",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08797",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08940",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08942",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08951",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Indoprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08955",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Ibuproxam is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08976",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08981",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08984",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08991",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09084",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09213",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Dexibuprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09214",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09215",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09216",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09217",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Firocoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09218",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Clonixin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09285",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Morniflumate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09288",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Propacetamol is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09295",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Talniflumate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11455",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Robenacoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11466",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Tepoxalin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11518",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Flunixin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12399",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Polmacoxib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12445",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Nitroaspirin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12545",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Indobufen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12610",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Ebselen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13001",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Tinoridine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13167",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Alclofenac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13217",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Fentiazac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13232",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Suxibuzone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13286",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Bumadizone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13314",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13371",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Difenpiramide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13407",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Nifenazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13432",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Lonazolac is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13481",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Tenidap is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13524",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Propyphenazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13527",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Proglumetacin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13538",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Guacetisal is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13544",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Ethenzamide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13612",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Carbaspirin calcium is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13629",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Mofebutazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13649",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Proquazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13657",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Benorilate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13722",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Pirprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13783",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13860",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Imidazole salicylate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB14059",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when SC 236 is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB14060",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when NS 398 is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB14938",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen axetil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09212",
                        "description": "The risk or severity of gastrointestinal bleeding can be increased when Loxoprofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00017",
                        "description": "The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06773",
                        "description": "The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13189",
                        "description": "The risk or severity of hypocalcemia can be increased when Calcitonin porcine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13742",
                        "description": "The risk or severity of hypocalcemia can be increased when Elcatonin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00314",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00452",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00479",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00684",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00798",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00955",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00994",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01082",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01172",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01421",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB03615",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ribostamycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04263",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Geneticin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04626",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04729",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin C1a is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04808",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neamine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06696",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08437",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Puromycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11512",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11520",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hygromycin B is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12604",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12615",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13540",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Isepamicin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00803",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01370",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Aluminium"
                    },
                    {
                        "drugbank-id": "DB01377",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide"
                    },
                    {
                        "drugbank-id": "DB01390",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Sodium bicarbonate"
                    },
                    {
                        "drugbank-id": "DB06723",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide"
                    },
                    {
                        "drugbank-id": "DB06724",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium carbonate"
                    },
                    {
                        "drugbank-id": "DB08938",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Magaldrate"
                    },
                    {
                        "drugbank-id": "DB09104",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide"
                    },
                    {
                        "drugbank-id": "DB09281",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Magnesium trisilicate"
                    },
                    {
                        "drugbank-id": "DB09481",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Magnesium carbonate"
                    },
                    {
                        "drugbank-id": "DB13209",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Bismuth subnitrate"
                    },
                    {
                        "drugbank-id": "DB13249",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Magnesium silicate"
                    },
                    {
                        "drugbank-id": "DB13280",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Aluminium acetoacetate"
                    },
                    {
                        "drugbank-id": "DB13322",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Hydrotalcite"
                    },
                    {
                        "drugbank-id": "DB13486",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Magnesium peroxide"
                    },
                    {
                        "drugbank-id": "DB13595",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Almasilate"
                    },
                    {
                        "drugbank-id": "DB13626",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Aluminium glycinate"
                    },
                    {
                        "drugbank-id": "DB13650",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Aloglutamol"
                    },
                    {
                        "drugbank-id": "DB13829",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium silicate"
                    },
                    {
                        "drugbank-id": "DB14517",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Aluminium phosphate"
                    },
                    {
                        "drugbank-id": "DB00007",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Leuprolide"
                    },
                    {
                        "drugbank-id": "DB00014",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Goserelin"
                    },
                    {
                        "drugbank-id": "DB00195",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Betaxolol"
                    },
                    {
                        "drugbank-id": "DB00199",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erythromycin"
                    },
                    {
                        "drugbank-id": "DB00207",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azithromycin"
                    },
                    {
                        "drugbank-id": "DB00218",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Moxifloxacin"
                    },
                    {
                        "drugbank-id": "DB00243",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ranolazine"
                    },
                    {
                        "drugbank-id": "DB00263",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulfisoxazole"
                    },
                    {
                        "drugbank-id": "DB00321",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amitriptyline"
                    },
                    {
                        "drugbank-id": "DB00333",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methadone"
                    },
                    {
                        "drugbank-id": "DB00343",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Diltiazem"
                    },
                    {
                        "drugbank-id": "DB00363",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clozapine"
                    },
                    {
                        "drugbank-id": "DB00391",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sulpiride"
                    },
                    {
                        "drugbank-id": "DB00393",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nimodipine"
                    },
                    {
                        "drugbank-id": "DB00420",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Promazine"
                    },
                    {
                        "drugbank-id": "DB00433",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prochlorperazine"
                    },
                    {
                        "drugbank-id": "DB00450",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Droperidol"
                    },
                    {
                        "drugbank-id": "DB00458",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imipramine"
                    },
                    {
                        "drugbank-id": "DB00477",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorpromazine"
                    },
                    {
                        "drugbank-id": "DB00526",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxaliplatin"
                    },
                    {
                        "drugbank-id": "DB00537",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ciprofloxacin"
                    },
                    {
                        "drugbank-id": "DB00544",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluorouracil"
                    },
                    {
                        "drugbank-id": "DB00556",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Perflutren"
                    },
                    {
                        "drugbank-id": "DB00568",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cinnarizine"
                    },
                    {
                        "drugbank-id": "DB00571",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propranolol"
                    },
                    {
                        "drugbank-id": "DB00572",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Atropine"
                    },
                    {
                        "drugbank-id": "DB00608",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chloroquine"
                    },
                    {
                        "drugbank-id": "DB00625",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Efavirenz"
                    },
                    {
                        "drugbank-id": "DB00640",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Adenosine"
                    },
                    {
                        "drugbank-id": "DB00743",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gadobenic acid"
                    },
                    {
                        "drugbank-id": "DB00748",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Carbinoxamine"
                    },
                    {
                        "drugbank-id": "DB00757",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dolasetron"
                    },
                    {
                        "drugbank-id": "DB00778",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Roxithromycin"
                    },
                    {
                        "drugbank-id": "DB00779",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nalidixic acid"
                    },
                    {
                        "drugbank-id": "DB00827",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cinoxacin"
                    },
                    {
                        "drugbank-id": "DB00836",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Loperamide"
                    },
                    {
                        "drugbank-id": "DB00889",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Granisetron"
                    },
                    {
                        "drugbank-id": "DB00904",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ondansetron"
                    },
                    {
                        "drugbank-id": "DB00922",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levosimendan"
                    },
                    {
                        "drugbank-id": "DB00933",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mesoridazine"
                    },
                    {
                        "drugbank-id": "DB00967",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desloratadine"
                    },
                    {
                        "drugbank-id": "DB00976",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Telithromycin"
                    },
                    {
                        "drugbank-id": "DB00978",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lomefloxacin"
                    },
                    {
                        "drugbank-id": "DB00985",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dimenhydrinate"
                    },
                    {
                        "drugbank-id": "DB01087",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Primaquine"
                    },
                    {
                        "drugbank-id": "DB01113",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Papaverine"
                    },
                    {
                        "drugbank-id": "DB01114",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorpheniramine"
                    },
                    {
                        "drugbank-id": "DB01115",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nifedipine"
                    },
                    {
                        "drugbank-id": "DB01137",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levofloxacin"
                    },
                    {
                        "drugbank-id": "DB01155",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gemifloxacin"
                    },
                    {
                        "drugbank-id": "DB01165",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ofloxacin"
                    },
                    {
                        "drugbank-id": "DB01182",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propafenone"
                    },
                    {
                        "drugbank-id": "DB01193",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acebutolol"
                    },
                    {
                        "drugbank-id": "DB01195",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flecainide"
                    },
                    {
                        "drugbank-id": "DB01211",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clarithromycin"
                    },
                    {
                        "drugbank-id": "DB01227",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levacetylmethadol"
                    },
                    {
                        "drugbank-id": "DB01232",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Saquinavir"
                    },
                    {
                        "drugbank-id": "DB01242",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clomipramine"
                    },
                    {
                        "drugbank-id": "DB01388",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mibefradil"
                    },
                    {
                        "drugbank-id": "DB01580",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxprenolol"
                    },
                    {
                        "drugbank-id": "DB01599",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Probucol"
                    },
                    {
                        "drugbank-id": "DB01615",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aceprometazine"
                    },
                    {
                        "drugbank-id": "DB02638",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terlipressin"
                    },
                    {
                        "drugbank-id": "DB04825",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prenylamine"
                    },
                    {
                        "drugbank-id": "DB04842",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluspirilene"
                    },
                    {
                        "drugbank-id": "DB04948",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lofexidine"
                    },
                    {
                        "drugbank-id": "DB04957",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azimilide"
                    },
                    {
                        "drugbank-id": "DB05223",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pracinostat"
                    },
                    {
                        "drugbank-id": "DB05488",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Technetium Tc 99m ciprofloxacin"
                    },
                    {
                        "drugbank-id": "DB06160",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Garenoxacin"
                    },
                    {
                        "drugbank-id": "DB06200",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tedisamil"
                    },
                    {
                        "drugbank-id": "DB06334",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tucidinostat"
                    },
                    {
                        "drugbank-id": "DB06402",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Telavancin"
                    },
                    {
                        "drugbank-id": "DB06600",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nemonoxacin"
                    },
                    {
                        "drugbank-id": "DB06603",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Panobinostat"
                    },
                    {
                        "drugbank-id": "DB06712",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nilvadipine"
                    },
                    {
                        "drugbank-id": "DB08799",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Antazoline"
                    },
                    {
                        "drugbank-id": "DB08865",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Crizotinib"
                    },
                    {
                        "drugbank-id": "DB08903",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bedaquiline"
                    },
                    {
                        "drugbank-id": "DB08952",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indenolol"
                    },
                    {
                        "drugbank-id": "DB08980",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fendiline"
                    },
                    {
                        "drugbank-id": "DB08992",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eperisone"
                    },
                    {
                        "drugbank-id": "DB09016",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Butriptyline"
                    },
                    {
                        "drugbank-id": "DB09063",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ceritinib"
                    },
                    {
                        "drugbank-id": "DB09078",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lenvatinib"
                    },
                    {
                        "drugbank-id": "DB09224",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Melperone"
                    },
                    {
                        "drugbank-id": "DB09231",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Benidipine"
                    },
                    {
                        "drugbank-id": "DB09555",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexchlorpheniramine maleate"
                    },
                    {
                        "drugbank-id": "DB11640",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amifampridine"
                    },
                    {
                        "drugbank-id": "DB11830",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mocetinostat"
                    },
                    {
                        "drugbank-id": "DB11841",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Entinostat"
                    },
                    {
                        "drugbank-id": "DB12141",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gilteritinib"
                    },
                    {
                        "drugbank-id": "DB12174",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with CUDC 101"
                    },
                    {
                        "drugbank-id": "DB12286",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Simendan"
                    },
                    {
                        "drugbank-id": "DB12376",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ricolinostat"
                    },
                    {
                        "drugbank-id": "DB12523",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mizolastine"
                    },
                    {
                        "drugbank-id": "DB12565",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Abexinostat"
                    },
                    {
                        "drugbank-id": "DB12877",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxatomide"
                    },
                    {
                        "drugbank-id": "DB13261",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sitafloxacin"
                    },
                    {
                        "drugbank-id": "DB13273",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sultopride"
                    },
                    {
                        "drugbank-id": "DB13500",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Otilonium"
                    },
                    {
                        "drugbank-id": "DB13546",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nizofenone"
                    },
                    {
                        "drugbank-id": "DB13652",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bunaftine"
                    },
                    {
                        "drugbank-id": "DB13653",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lorcainide"
                    },
                    {
                        "drugbank-id": "DB13679",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexchlorpheniramine"
                    },
                    {
                        "drugbank-id": "DB13791",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Penfluridol"
                    },
                    {
                        "drugbank-id": "DB14063",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexverapamil"
                    },
                    {
                        "drugbank-id": "DB14568",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivosidenib"
                    },
                    {
                        "drugbank-id": "DB01224",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quetiapine"
                    },
                    {
                        "drugbank-id": "DB11718",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Encorafenib"
                    },
                    {
                        "drugbank-id": "DB01084",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Emedastine"
                    },
                    {
                        "drugbank-id": "DB15982",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Berotralstat"
                    },
                    {
                        "drugbank-id": "DB00204",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dofetilide"
                    },
                    {
                        "drugbank-id": "DB00215",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Citalopram"
                    },
                    {
                        "drugbank-id": "DB00261",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Anagrelide"
                    },
                    {
                        "drugbank-id": "DB00280",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disopyramide"
                    },
                    {
                        "drugbank-id": "DB00283",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clemastine"
                    },
                    {
                        "drugbank-id": "DB00308",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ibutilide"
                    },
                    {
                        "drugbank-id": "DB00313",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Valproic acid"
                    },
                    {
                        "drugbank-id": "DB00342",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terfenadine"
                    },
                    {
                        "drugbank-id": "DB00365",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Grepafloxacin"
                    },
                    {
                        "drugbank-id": "DB00468",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinine"
                    },
                    {
                        "drugbank-id": "DB00489",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sotalol"
                    },
                    {
                        "drugbank-id": "DB00530",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erlotinib"
                    },
                    {
                        "drugbank-id": "DB00539",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Toremifene"
                    },
                    {
                        "drugbank-id": "DB00604",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cisapride"
                    },
                    {
                        "drugbank-id": "DB00619",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imatinib"
                    },
                    {
                        "drugbank-id": "DB00637",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Astemizole"
                    },
                    {
                        "drugbank-id": "DB00679",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thioridazine"
                    },
                    {
                        "drugbank-id": "DB00685",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trovafloxacin"
                    },
                    {
                        "drugbank-id": "DB00834",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mifepristone"
                    },
                    {
                        "drugbank-id": "DB00875",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flupentixol"
                    },
                    {
                        "drugbank-id": "DB00907",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cocaine"
                    },
                    {
                        "drugbank-id": "DB00908",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinidine"
                    },
                    {
                        "drugbank-id": "DB01035",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Procainamide"
                    },
                    {
                        "drugbank-id": "DB01100",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pimozide"
                    },
                    {
                        "drugbank-id": "DB01118",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amiodarone"
                    },
                    {
                        "drugbank-id": "DB01169",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Arsenic trioxide"
                    },
                    {
                        "drugbank-id": "DB01175",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Escitalopram"
                    },
                    {
                        "drugbank-id": "DB01184",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Domperidone"
                    },
                    {
                        "drugbank-id": "DB01208",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sparfloxacin"
                    },
                    {
                        "drugbank-id": "DB01218",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Halofantrine"
                    },
                    {
                        "drugbank-id": "DB01244",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bepridil"
                    },
                    {
                        "drugbank-id": "DB01267",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paliperidone"
                    },
                    {
                        "drugbank-id": "DB01356",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lithium cation"
                    },
                    {
                        "drugbank-id": "DB01405",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Temafloxacin"
                    },
                    {
                        "drugbank-id": "DB01624",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Zuclopenthixol"
                    },
                    {
                        "drugbank-id": "DB04844",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tetrabenazine"
                    },
                    {
                        "drugbank-id": "DB04855",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dronedarone"
                    },
                    {
                        "drugbank-id": "DB04868",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nilotinib"
                    },
                    {
                        "drugbank-id": "DB04946",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Iloperidone"
                    },
                    {
                        "drugbank-id": "DB05294",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vandetanib"
                    },
                    {
                        "drugbank-id": "DB06176",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Romidepsin"
                    },
                    {
                        "drugbank-id": "DB06216",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Asenapine"
                    },
                    {
                        "drugbank-id": "DB06697",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Artemether"
                    },
                    {
                        "drugbank-id": "DB06708",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lumefantrine"
                    },
                    {
                        "drugbank-id": "DB09039",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eliglustat"
                    },
                    {
                        "drugbank-id": "DB09083",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivabradine"
                    },
                    {
                        "drugbank-id": "DB11730",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ribociclib"
                    },
                    {
                        "drugbank-id": "DB11978",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Glasdegib"
                    },
                    {
                        "drugbank-id": "DB12161",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Deutetrabenazine"
                    },
                    {
                        "drugbank-id": "DB13074",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Macimorelin"
                    },
                    {
                        "drugbank-id": "DB13725",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terodiline"
                    },
                    {
                        "drugbank-id": "DB00325",
                        "description": "Nitroprusside can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB06783",
                        "description": "Prussian blue can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09146",
                        "description": "Iron sucrose can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09501",
                        "description": "Ferric ammonium citrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09507",
                        "description": "Ferumoxsil can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09508",
                        "description": "Ferumoxides can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11171",
                        "description": "Ferric sulfate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11210",
                        "description": "Ferrous bisglycinate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11417",
                        "description": "Gleptoferron can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11576",
                        "description": "Ferric oxide can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB12821",
                        "description": "Perflubutane can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13257",
                        "description": "Ferrous sulfate anhydrous can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13381",
                        "description": "Sodium feredetate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13423",
                        "description": "Ferric hydroxide can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13569",
                        "description": "Ferrous chloride can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13949",
                        "description": "Ferric cation can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14488",
                        "description": "Ferrous gluconate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14489",
                        "description": "Ferrous succinate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14491",
                        "description": "Ferrous fumarate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14520",
                        "description": "Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14695",
                        "description": "Ferric oxyhydroxide can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB15598",
                        "description": "Ferric maltol can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB12208",
                        "description": "Iron isomaltoside 1000 can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB00653",
                        "description": "Magnesium sulfate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB09407",
                        "description": "Magnesium chloride can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB11110",
                        "description": "Magnesium citrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13359",
                        "description": "Magnesium aspartate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13749",
                        "description": "Magnesium gluconate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB13786",
                        "description": "Magnesium orotate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14514",
                        "description": "Magnesium levulinate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB14515",
                        "description": "Magnesium lactate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB00258",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium acetate"
                    },
                    {
                        "drugbank-id": "DB00326",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium glucoheptonate"
                    },
                    {
                        "drugbank-id": "DB01164",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium chloride"
                    },
                    {
                        "drugbank-id": "DB01373",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium"
                    },
                    {
                        "drugbank-id": "DB11093",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium citrate"
                    },
                    {
                        "drugbank-id": "DB11126",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate"
                    },
                    {
                        "drugbank-id": "DB11348",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium Phosphate"
                    },
                    {
                        "drugbank-id": "DB13142",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate anhydrous"
                    },
                    {
                        "drugbank-id": "DB13231",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate"
                    },
                    {
                        "drugbank-id": "DB13365",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium lactate gluconate"
                    },
                    {
                        "drugbank-id": "DB13590",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium pangamate"
                    },
                    {
                        "drugbank-id": "DB13800",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium levulinate"
                    },
                    {
                        "drugbank-id": "DB14577",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium cation"
                    },
                    {
                        "drugbank-id": "DB14684",
                        "description": "The serum concentration of Ibandronate can be decreased when it is combined with Calcium polycarbophil"
                    },
                    {
                        "drugbank-id": "DB08881",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vemurafenib"
                    },
                    {
                        "drugbank-id": "DB09139",
                        "description": "The risk or severity of hypocalcemia can be increased when Ibandronate is combined with Technetium Tc 99m oxidronate"
                    },
                    {
                        "drugbank-id": "DB11637",
                        "description": "Ibandronate may increase the QTc prolonging activities of Delamanid"
                    },
                    {
                        "drugbank-id": "DB00214",
                        "description": "The risk or severity of hypocalcemia can be increased when Torasemide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00695",
                        "description": "The risk or severity of hypocalcemia can be increased when Furosemide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00887",
                        "description": "The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00903",
                        "description": "The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB02925",
                        "description": "The risk or severity of hypocalcemia can be increased when Piretanide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB08961",
                        "description": "The risk or severity of hypocalcemia can be increased when Azosemide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00091",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00229",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00267",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmenoxime is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00274",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00282",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00300",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00369",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cidofovir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00384",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Triamterene is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00430",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpiramide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00438",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00447",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00456",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00493",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00512",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00515",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00529",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00563",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Methotrexate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00567",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00577",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Valaciclovir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00626",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00681",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00689",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephaloglycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00718",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00738",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pentamidine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00742",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00787",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00833",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00864",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00923",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00958",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00999",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrochlorothiazide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01066",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01072",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Atazanavir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01111",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistimethate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01112",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01139",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01140",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01150",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01212",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01326",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01327",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01328",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01329",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01330",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01331",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01332",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01333",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01413",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01414",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefacetrile is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01415",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01416",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB02247",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrolyzed Cephalothin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB03450",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalothin Group is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04570",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB04918",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftobiprole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB06590",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09008",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaloridine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09062",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefminox is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB09299",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11367",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefroxadine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11935",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Flomoxef is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB12151",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Brincidofovir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13266",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13461",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefcapene is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13470",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13499",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13504",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13638",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefbuperazone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13667",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefozopran is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13682",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13778",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazedone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13821",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftezole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB13868",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB14126",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB14713",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Inotersen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB01438",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Phenazopyridine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB14507",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lithium citrate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB14509",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Lithium carbonate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB15066",
                        "description": "The risk or severity of nephrotoxicity and hypocalcemia can be increased when Givosiran is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00399",
                        "description": "The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00720",
                        "description": "The risk or severity of adverse effects can be increased when Ibandronate is combined with Clodronic acid"
                    },
                    {
                        "drugbank-id": "DB01077",
                        "description": "The risk or severity of adverse effects can be increased when Ibandronate is combined with Etidronic acid"
                    },
                    {
                        "drugbank-id": "DB01133",
                        "description": "The risk or severity of adverse effects can be increased when Ibandronate is combined with Tiludronic acid"
                    },
                    {
                        "drugbank-id": "DB06255",
                        "description": "The risk or severity of adverse effects can be increased when Ibandronate is combined with Incadronic acid"
                    },
                    {
                        "drugbank-id": "DB00104",
                        "description": "The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00107",
                        "description": "The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00187",
                        "description": "The risk or severity of QTc prolongation can be increased when Esmolol is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00188",
                        "description": "The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00196",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00220",
                        "description": "The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00230",
                        "description": "The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00245",
                        "description": "The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00270",
                        "description": "The risk or severity of QTc prolongation can be increased when Isradipine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00285",
                        "description": "The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00289",
                        "description": "The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00334",
                        "description": "The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00341",
                        "description": "The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00344",
                        "description": "The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00346",
                        "description": "The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00347",
                        "description": "The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00354",
                        "description": "The risk or severity of QTc prolongation can be increased when Buclizine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00366",
                        "description": "The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00370",
                        "description": "The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00373",
                        "description": "The risk or severity of QTc prolongation can be increased when Timolol is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00374",
                        "description": "The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00390",
                        "description": "The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00398",
                        "description": "The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00405",
                        "description": "The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00424",
                        "description": "The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00427",
                        "description": "The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00434",
                        "description": "The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00467",
                        "description": "The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00487",
                        "description": "The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00540",
                        "description": "The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00543",
                        "description": "The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00555",
                        "description": "The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00582",
                        "description": "The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00593",
                        "description": "The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00613",
                        "description": "The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00622",
                        "description": "The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00674",
                        "description": "The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00675",
                        "description": "The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00678",
                        "description": "The risk or severity of QTc prolongation can be increased when Losartan is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00680",
                        "description": "The risk or severity of QTc prolongation can be increased when Moricizine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00691",
                        "description": "The risk or severity of QTc prolongation can be increased when Moexipril is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00697",
                        "description": "The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00714",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Apomorphine"
                    },
                    {
                        "drugbank-id": "DB00719",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azatadine"
                    },
                    {
                        "drugbank-id": "DB00726",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trimipramine"
                    },
                    {
                        "drugbank-id": "DB00734",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Risperidone"
                    },
                    {
                        "drugbank-id": "DB00753",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Isoflurane"
                    },
                    {
                        "drugbank-id": "DB00808",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indapamide"
                    },
                    {
                        "drugbank-id": "DB00817",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rosoxacin"
                    },
                    {
                        "drugbank-id": "DB00822",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disulfiram"
                    },
                    {
                        "drugbank-id": "DB00825",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levomenthol"
                    },
                    {
                        "drugbank-id": "DB00835",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Brompheniramine"
                    },
                    {
                        "drugbank-id": "DB00862",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vardenafil"
                    },
                    {
                        "drugbank-id": "DB00871",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terbutaline"
                    },
                    {
                        "drugbank-id": "DB00909",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Zonisamide"
                    },
                    {
                        "drugbank-id": "DB00915",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amantadine"
                    },
                    {
                        "drugbank-id": "DB00916",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Metronidazole"
                    },
                    {
                        "drugbank-id": "DB00920",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ketotifen"
                    },
                    {
                        "drugbank-id": "DB00927",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Famotidine"
                    },
                    {
                        "drugbank-id": "DB00934",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Maprotiline"
                    },
                    {
                        "drugbank-id": "DB00949",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Felbamate"
                    },
                    {
                        "drugbank-id": "DB00983",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Formoterol"
                    },
                    {
                        "drugbank-id": "DB01001",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salbutamol"
                    },
                    {
                        "drugbank-id": "DB01023",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Felodipine"
                    },
                    {
                        "drugbank-id": "DB01026",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ketoconazole"
                    },
                    {
                        "drugbank-id": "DB01036",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tolterodine"
                    },
                    {
                        "drugbank-id": "DB01044",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gatifloxacin"
                    },
                    {
                        "drugbank-id": "DB01054",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nitrendipine"
                    },
                    {
                        "drugbank-id": "DB01069",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Promethazine"
                    },
                    {
                        "drugbank-id": "DB01071",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mequitazine"
                    },
                    {
                        "drugbank-id": "DB01074",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Perhexiline"
                    },
                    {
                        "drugbank-id": "DB01075",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Diphenhydramine"
                    },
                    {
                        "drugbank-id": "DB01106",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levocabastine"
                    },
                    {
                        "drugbank-id": "DB01142",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Doxepin"
                    },
                    {
                        "drugbank-id": "DB01151",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desipramine"
                    },
                    {
                        "drugbank-id": "DB01158",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bretylium"
                    },
                    {
                        "drugbank-id": "DB01166",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cilostazol"
                    },
                    {
                        "drugbank-id": "DB01167",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Itraconazole"
                    },
                    {
                        "drugbank-id": "DB01173",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Orphenadrine"
                    },
                    {
                        "drugbank-id": "DB01176",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cyclizine"
                    },
                    {
                        "drugbank-id": "DB01189",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desflurane"
                    },
                    {
                        "drugbank-id": "DB01228",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Encainide"
                    },
                    {
                        "drugbank-id": "DB01236",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sevoflurane"
                    },
                    {
                        "drugbank-id": "DB01238",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole"
                    },
                    {
                        "drugbank-id": "DB01239",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorprothixene"
                    },
                    {
                        "drugbank-id": "DB01246",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Alimemazine"
                    },
                    {
                        "drugbank-id": "DB01254",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dasatinib"
                    },
                    {
                        "drugbank-id": "DB01259",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lapatinib"
                    },
                    {
                        "drugbank-id": "DB01263",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Posaconazole"
                    },
                    {
                        "drugbank-id": "DB01274",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Arformoterol"
                    },
                    {
                        "drugbank-id": "DB01396",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Digitoxin"
                    },
                    {
                        "drugbank-id": "DB01403",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methotrimeprazine"
                    },
                    {
                        "drugbank-id": "DB01426",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ajmaline"
                    },
                    {
                        "drugbank-id": "DB01591",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Solifenacin"
                    },
                    {
                        "drugbank-id": "DB01611",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Hydroxychloroquine"
                    },
                    {
                        "drugbank-id": "DB01620",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pheniramine"
                    },
                    {
                        "drugbank-id": "DB01623",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thiothixene"
                    },
                    {
                        "drugbank-id": "DB02546",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vorinostat"
                    },
                    {
                        "drugbank-id": "DB04576",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fleroxacin"
                    },
                    {
                        "drugbank-id": "DB04695",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Farnesyl thiopyrophosphate"
                    },
                    {
                        "drugbank-id": "DB04846",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Celiprolol"
                    },
                    {
                        "drugbank-id": "DB04953",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ezogabine"
                    },
                    {
                        "drugbank-id": "DB05039",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indacaterol"
                    },
                    {
                        "drugbank-id": "DB05246",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methsuximide"
                    },
                    {
                        "drugbank-id": "DB05465",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tandutinib"
                    },
                    {
                        "drugbank-id": "DB06217",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vernakalant"
                    },
                    {
                        "drugbank-id": "DB06282",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levocetirizine"
                    },
                    {
                        "drugbank-id": "DB06288",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amisulpride"
                    },
                    {
                        "drugbank-id": "DB06468",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cariporide"
                    },
                    {
                        "drugbank-id": "DB06663",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pasireotide"
                    },
                    {
                        "drugbank-id": "DB06691",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mepyramine"
                    },
                    {
                        "drugbank-id": "DB06699",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Degarelix"
                    },
                    {
                        "drugbank-id": "DB06719",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Buserelin"
                    },
                    {
                        "drugbank-id": "DB06788",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Histrelin"
                    },
                    {
                        "drugbank-id": "DB06825",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triptorelin"
                    },
                    {
                        "drugbank-id": "DB07780",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Farnesyl diphosphate"
                    },
                    {
                        "drugbank-id": "DB07841",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Geranylgeranyl diphosphate"
                    },
                    {
                        "drugbank-id": "DB08808",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bupranolol"
                    },
                    {
                        "drugbank-id": "DB08815",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lurasidone"
                    },
                    {
                        "drugbank-id": "DB08864",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rilpivirine"
                    },
                    {
                        "drugbank-id": "DB08871",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08893",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mirabegron"
                    },
                    {
                        "drugbank-id": "DB08912",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dabrafenib"
                    },
                    {
                        "drugbank-id": "DB08936",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorcyclizine"
                    },
                    {
                        "drugbank-id": "DB08972",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flumequine"
                    },
                    {
                        "drugbank-id": "DB09080",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Olodaterol"
                    },
                    {
                        "drugbank-id": "DB09082",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vilanterol"
                    },
                    {
                        "drugbank-id": "DB09089",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trimebutine"
                    },
                    {
                        "drugbank-id": "DB09090",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pinaverium"
                    },
                    {
                        "drugbank-id": "DB09167",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dosulepin"
                    },
                    {
                        "drugbank-id": "DB09229",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aranidipine"
                    },
                    {
                        "drugbank-id": "DB09235",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Efonidipine"
                    },
                    {
                        "drugbank-id": "DB09236",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lacidipine"
                    },
                    {
                        "drugbank-id": "DB09239",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Niguldipine"
                    },
                    {
                        "drugbank-id": "DB09488",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acrivastine"
                    },
                    {
                        "drugbank-id": "DB11390",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Coumaphos"
                    },
                    {
                        "drugbank-id": "DB11397",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dichlorvos"
                    },
                    {
                        "drugbank-id": "DB11408",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Famphur"
                    },
                    {
                        "drugbank-id": "DB11412",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fenthion"
                    },
                    {
                        "drugbank-id": "DB11443",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Orbifloxacin"
                    },
                    {
                        "drugbank-id": "DB11448",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Phosmet"
                    },
                    {
                        "drugbank-id": "DB11491",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sarafloxacin"
                    },
                    {
                        "drugbank-id": "DB11511",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Difloxacin"
                    },
                    {
                        "drugbank-id": "DB11591",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bilastine"
                    },
                    {
                        "drugbank-id": "DB11614",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rupatadine"
                    },
                    {
                        "drugbank-id": "DB11742",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ebastine"
                    },
                    {
                        "drugbank-id": "DB11770",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Talinolol"
                    },
                    {
                        "drugbank-id": "DB11774",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pazufloxacin"
                    },
                    {
                        "drugbank-id": "DB11785",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Anisodamine"
                    },
                    {
                        "drugbank-id": "DB11891",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with CUDC 907"
                    },
                    {
                        "drugbank-id": "DB11892",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prulifloxacin"
                    },
                    {
                        "drugbank-id": "DB11943",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Delafloxacin"
                    },
                    {
                        "drugbank-id": "DB12093",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tetrahydropalmatine"
                    },
                    {
                        "drugbank-id": "DB12231",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Temefos"
                    },
                    {
                        "drugbank-id": "DB12245",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triclabendazole"
                    },
                    {
                        "drugbank-id": "DB12645",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Givinostat"
                    },
                    {
                        "drugbank-id": "DB12712",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pilsicainide"
                    },
                    {
                        "drugbank-id": "DB12766",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cicletanine"
                    },
                    {
                        "drugbank-id": "DB12923",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gallopamil"
                    },
                    {
                        "drugbank-id": "DB13358",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cibenzoline"
                    },
                    {
                        "drugbank-id": "DB13488",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bencyclane"
                    },
                    {
                        "drugbank-id": "DB13555",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prajmaline"
                    },
                    {
                        "drugbank-id": "DB13627",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxolinic acid"
                    },
                    {
                        "drugbank-id": "DB13651",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lorajmine"
                    },
                    {
                        "drugbank-id": "DB13691",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acetyldigoxin"
                    },
                    {
                        "drugbank-id": "DB13744",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Piromidic acid"
                    },
                    {
                        "drugbank-id": "DB13766",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lidoflazine"
                    },
                    {
                        "drugbank-id": "DB13772",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rufloxacin"
                    },
                    {
                        "drugbank-id": "DB13823",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pipemidic acid"
                    },
                    {
                        "drugbank-id": "DB14185",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole lauroxil"
                    },
                    {
                        "drugbank-id": "DB01601",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lopinavir"
                    },
                    {
                        "drugbank-id": "DB00845",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clofazimine"
                    },
                    {
                        "drugbank-id": "DB11796",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fostemsavir"
                    },
                    {
                        "drugbank-id": "DB00751",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Epinastine"
                    },
                    {
                        "drugbank-id": "DB11853",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Relugolix"
                    },
                    {
                        "drugbank-id": "DB00052",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Somatotropin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00065",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Infliximab is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00080",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Daptomycin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00175",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Pravastatin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00181",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Baclofen is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00203",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Sildenafil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00224",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Indinavir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00227",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Lovastatin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00242",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Cladribine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00252",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Phenytoin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00358",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Mefloquine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00382",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Tacrine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00389",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Carbimazole is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00439",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Cerivastatin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00440",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Trimethoprim is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00443",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Betamethasone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00471",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Montelukast is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00495",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Zidovudine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00501",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Cimetidine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ritonavir is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00528",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Lercanidipine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Vincristine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00550",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Propylthiouracil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00584",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Enalapril is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00585",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Nizatidine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00602",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ivermectin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00620",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Triamcinolone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00627",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Niacin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00630",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Alendronic acid is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00636",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Clofibrate is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00641",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Simvastatin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00649",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Stavudine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00666",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Nafarelin is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00688",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Mycophenolate mofetil is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00704",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Naltrexone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00709",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Lamivudine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00818",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Propofol"
                    },
                    {
                        "drugbank-id": "DB00857",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Terbinafine"
                    },
                    {
                        "drugbank-id": "DB00859",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Penicillamine"
                    },
                    {
                        "drugbank-id": "DB00863",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Ranitidine"
                    },
                    {
                        "drugbank-id": "DB00876",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Eprosartan"
                    },
                    {
                        "drugbank-id": "DB00884",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Risedronic acid"
                    },
                    {
                        "drugbank-id": "DB00897",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Triazolam"
                    },
                    {
                        "drugbank-id": "DB00898",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Ethanol"
                    },
                    {
                        "drugbank-id": "DB00938",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Salmeterol"
                    },
                    {
                        "drugbank-id": "DB00951",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Isoniazid"
                    },
                    {
                        "drugbank-id": "DB00968",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Methyldopa"
                    },
                    {
                        "drugbank-id": "DB00982",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Isotretinoin"
                    },
                    {
                        "drugbank-id": "DB00987",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Cytarabine"
                    },
                    {
                        "drugbank-id": "DB01004",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Ganciclovir"
                    },
                    {
                        "drugbank-id": "DB01006",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Letrozole"
                    },
                    {
                        "drugbank-id": "DB01015",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Sulfamethoxazole"
                    },
                    {
                        "drugbank-id": "DB01017",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Minocycline"
                    },
                    {
                        "drugbank-id": "DB01039",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Fenofibrate"
                    },
                    {
                        "drugbank-id": "DB01059",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Norfloxacin"
                    },
                    {
                        "drugbank-id": "DB01076",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Atorvastatin"
                    },
                    {
                        "drugbank-id": "DB01088",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Iloprost"
                    },
                    {
                        "drugbank-id": "DB01095",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Fluvastatin"
                    },
                    {
                        "drugbank-id": "DB01097",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Leflunomide"
                    },
                    {
                        "drugbank-id": "DB01098",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Rosuvastatin"
                    },
                    {
                        "drugbank-id": "DB01168",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Procarbazine"
                    },
                    {
                        "drugbank-id": "DB01197",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Captopril"
                    },
                    {
                        "drugbank-id": "DB01229",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Paclitaxel"
                    },
                    {
                        "drugbank-id": "DB01233",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Metoclopramide"
                    },
                    {
                        "drugbank-id": "DB01234",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Dexamethasone"
                    },
                    {
                        "drugbank-id": "DB01241",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Gemfibrozil"
                    },
                    {
                        "drugbank-id": "DB01248",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Docetaxel"
                    },
                    {
                        "drugbank-id": "DB01393",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Bezafibrate"
                    },
                    {
                        "drugbank-id": "DB01394",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Colchicine"
                    },
                    {
                        "drugbank-id": "DB02703",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Fusidic acid"
                    },
                    {
                        "drugbank-id": "DB05109",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Trabectedin"
                    },
                    {
                        "drugbank-id": "DB06693",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Mevastatin"
                    },
                    {
                        "drugbank-id": "DB06817",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Raltegravir"
                    },
                    {
                        "drugbank-id": "DB08860",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Pitavastatin"
                    },
                    {
                        "drugbank-id": "DB08983",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Etofibrate"
                    },
                    {
                        "drugbank-id": "DB09055",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Acipimox"
                    },
                    {
                        "drugbank-id": "DB09064",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Ciprofibrate"
                    },
                    {
                        "drugbank-id": "DB09270",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Ubidecarenone"
                    },
                    {
                        "drugbank-id": "DB09289",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Tianeptine"
                    },
                    {
                        "drugbank-id": "DB12554",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Mebeverine"
                    },
                    {
                        "drugbank-id": "DB13293",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Ipecac"
                    },
                    {
                        "drugbank-id": "DB13393",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Emetine"
                    },
                    {
                        "drugbank-id": "DB13433",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Simfibrate"
                    },
                    {
                        "drugbank-id": "DB13460",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Ronifibrate"
                    },
                    {
                        "drugbank-id": "DB13780",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Aluminium clofibrate"
                    },
                    {
                        "drugbank-id": "DB13849",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Clofibride"
                    },
                    {
                        "drugbank-id": "DB13873",
                        "description": "The risk or severity of myopathy rhabdomyolysis and myoglobinuria can be increased when Ibandronate is combined with Fenofibric acid"
                    },
                    {
                        "drugbank-id": "DB05829",
                        "description": "The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00656",
                        "description": "The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB11986",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Entrectinib"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "Ibandronate may increase the QTc prolonging activities of Pitolisant"
                    },
                    {
                        "drugbank-id": "DB12825",
                        "description": "Lefamulin may increase the QTc prolonging activities of Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00557",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00246",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone"
                    },
                    {
                        "drugbank-id": "DB14513",
                        "description": "Magnesium can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Haloperidol"
                    },
                    {
                        "drugbank-id": "DB00472",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ibandronate"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}